,uuid,title,publisher,link,providerPublishTime,type
0,a71ae5cd-498c-3c46-9146-6971cec11858,How Pfizer's $6.7 Billion Arena Pharmaceuticals Buyout Could Work for Investors,Motley Fool,https://finance.yahoo.com/m/a71ae5cd-498c-3c46-9146-6971cec11858/how-pfizer%27s-%246.7-billion.html,1648287240,STORY
1,65842172-0a5f-3e11-a038-656470ec1425,AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study,Zacks,https://finance.yahoo.com/news/astrazenecas-azn-imfinzi-misses-goal-182406237.html,1648232646,STORY
2,b6d2384b-4c75-3c7f-8351-9587dd0dca04,Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?,Zacks,https://finance.yahoo.com/news/bristol-myers-bmy-gains-16-154903577.html,1648223343,STORY
3,7f6e679d-0aab-3356-8d01-14eaf71630df,FDA Pushes Bristol Myers' Reblozyl Decision Date In Non-Transfusion Dependent Beta Thalassemia,Benzinga,https://finance.yahoo.com/news/fda-pushes-bristol-myers-reblozyl-131327471.html,1648214007,STORY
4,03aff1a5-b94a-3ee1-85ea-482e288677e2,Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for ReblozylÂ® (luspatercept-aamt) Supplemental Biologics License Application,Business Wire,https://finance.yahoo.com/news/bristol-myers-squibb-announces-prescription-105900565.html,1648205940,STORY
5,c230ad34-f4ab-3184-87c7-c1e97b48dad6,"How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag",Investor's Business Daily,https://finance.yahoo.com/m/c230ad34-f4ab-3184-87c7-c1e97b48dad6/how-rivals-merck%2C-bristol.html,1648154517,STORY
6,3fbe8bc1-7ac7-35ff-b5fe-e1effb91382a,Living Out Our Commitment for Patients: MS Awareness Month 2022,News Direct,https://finance.yahoo.com/news/living-commitment-patients-ms-awareness-130217885.html,1648126937,STORY
7,be40f621-f6e0-3320-b15b-eb0f79d0ff58,Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know,Zacks,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-214509014.html,1647985509,STORY
